BLAINJECTIONINJECTABLE
Approved
Apr 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
DYSPORT (botulinum toxin type a) by Ipsen is acetylcholine release inhibitors [moa]. First approved in 2009.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYSPORT is a botulinum toxin type A injection approved by the FDA in 2009 for aesthetic and therapeutic indications. It works by inhibiting acetylcholine release at the neuromuscular junction, temporarily paralyzing muscles. The drug is administered via injection and is used primarily in cosmetic dermatology and neurological conditions.
$0.003BPart D
LOE ApproachingStable
Product approaching loss of exclusivity with modest Part D spending suggests a mature, stable commercial footprint with potential team restructuring ahead.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)
Started Sep 2024
50 enrolled
Traumatic Brain Injury
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants
Started Oct 2023
249 enrolled
Masseter Muscle Prominence
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Started Oct 2023
759 enrolled
Chronic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Started Sep 2023
751 enrolled
Episodic Migraine
Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.
Started May 2022
121 enrolled
Post-Stroke Chronic Upper Limb Spasticity
Worked on DYSPORT at Ipsen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.